Dan S. Kaufman

Dan S. Kaufman, M.D., Ph.D., is a Co-Founder and board member of Shoreline Biosciences. Dr. Kaufman is a Professor in Department of Medicine, Division of Regenerative Medicine and Director of the Cell Therapy program at the University of California-San Diego (UCSD). Following undergraduate studies at Stanford University, he completed a combined MD/PhD program at Mayo Clinic and a clinical residency and fellowship in internal medicine and hematology at the University of Wisconsin-Madison. Dr. Kaufman is practicing clinical work in hematology and blood and marrow transplantation (BMT). His research focuses on use of human pluripotent stem cells to study development of hematopoietic stem/progenitor cells, lymphocytes and other immune cells. His studies as a post-doctoral fellow were the first to derive blood cells from human pluripotent stem cells. His laboratory was the first to produce functional lymphocytes from human pluripotent stem cells. More recently, his research efforts have focused on development of efficient means to produce natural killer (NK) cells from human pluripotent stem cells. His laboratory has pioneered strategies including novel NK-specific chimeric antigen receptors and other gene editing approaches that increase NK cell-mediated activity. Dr. Kaufman also leads the Advanced Cell Therapy Laboratory (ACTL), a GMP facility at UCSD to translate novel cell-based therapies into clinical trials and continues to practice clinical work.